Status:
COMPLETED
Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza
Lead Sponsor:
michael macknin
Collaborating Sponsors:
Pharmacare Laboratories
Conditions:
Influenza, Human
Eligibility:
All Genders
5+ years
Phase:
PHASE4
Brief Summary
This research is being done to determine if an extract of cooked elderberries will help decrease the duration and severity of influenza symptoms in patients with confirmed influenza. Involvement in th...
Eligibility Criteria
Inclusion
- With 48 hours or less of an influenza illness documented by polymerase chain reaction
- Have AT LEAST 2 of the following 7 influenza symptoms (nasal congestion, sore throat, cough, aches and pains, fatigue, headaches, and chills or sweats) graded as either moderate or severe
- Have access to a phone
- Subjects are capable of giving informed consent or have an acceptable legally authorized representative capable of giving consent on the subject's behalf with informed assent given by subject.
- Have been prescribed or offered a prescription for oseltamivir (Tamiflu)
Exclusion
- Known allergy to elderberry extract or oseltamivir
- Use of antibiotic or antiviral medication on presentation to the study
- Women who are pregnant, breastfeeding women, or do not agree to appropriate contraception (abstinence, hormonal, intrauterine device, and barrier) to prevent pregnancy during the study.
- Patients with HIV
- Patients with cystic fibrosis
- Patients taking elderberry extract
Key Trial Info
Start Date :
January 29 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 25 2019
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT03410862
Start Date
January 29 2018
End Date
June 25 2019
Last Update
January 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic
Cleveland, Ohio, United States, 44195